Unlocking the Mysteries of the Brain

The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). We are interested in working collaboratively with clinicians and researchers to use our blood-based assay technology to further biomarker exploration in neurologic disorders.

Exosomes are extremely small, membrane-bound vesicles produced by cells throughout the body. NanoSomiX is specifically focused on BDEs produced by various brain cell populations. A characteristic of BDEs is that they carry brain-produced biomarkers that relate to brain function and are released into the blood stream. As a result, BDE biomarker assessment can be done using a simple blood draw and can provide information on the status of tissue in the brain.

Our laboratory is working with both academic researchers and commercial companies to support ongoing research into biomarkers associated with various neurologic disorders and neurotrauma. Much of our contract work involves studies to confirm the detection of BDE biomarkers of interest, and to design protocols for diagnostic and monitoring applications. Working within a CLIA laboratory environment, we can provide a blood-based assay that is repeatable, cost effective and fits easily into a routine diagnostic or research environment.

Our proprietary exosome isolation and analysis technologies are covered by a series of recently granted patents, with several additional patent applications in process to cover various aspects of BDE processing and marker application. Using BDEs to explore clinical applications in neurologic disorders is supported by several peer-reviewed publications.

News and Events

8/6/19 – New study shows microRNA extracted from neuron-derived exosomes in ALS patient plasma may represent useful biomarkers

In a study published in Neuronscience Letters, the investigators state their "data suggest that miRNAs extracted from neuron-derived EV's in plasma reflect miRNA alterations in the brain as potential biomarkers of ALS".

Read More

11/19/18 - A study of enumerated blood plasma Brain-derived Exosomes (BDE) demonstrated potential usefulness as diagnostic and severity biomarkers for PD, MSA and PSP

A study published in the journal Parkinsonism and Related Disorders indicates that enumeration of neuron-derived exosomes (NDE), astrocyte-derived exosomes (ADE) and oligodendrocyte exosomes (ODE) may be useful as blood based biomarkers.

Read More

7/17/18 – Published study highlights a potential role for neuron-derived exosomes (NDE) in revealing the pathophysiology of brain diseases

In a study published in the Journal of Affective Disorders, analysis of NDE-related biomarkers isolated from peripheral blood suggest that this method may provide objective diagnostic indicators for patients with major depressive disorder (MDD).

Read More

5/18/18 - NanoSomiX, Inc. Announces Issuance of First US Patent

NanoSomiX, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the company’s first patent covering its groundbreaking proprietary exosome isolation and biomarker detection technology.

Read More

4/12/18 - Published study shows biomarker promise for neurotrauma recovery monitoring

NanoSomiX has further expanded its diagnostic applications which utilize its patented Brain Derived Exosome technology. A recently published study in Frontiers in Neurology tested a unique panel of blood biomarkers using this enhanced approach to evaluate the recovery process after sport-related neurotrauma.

Read More

In The News